Stay informed with the latest litigation news. Explore now

Therapeutic Compositions Containing Macitentan - EP2315587B1

EP2315587

ACTELION PHARMACEUTICALS
Application Number
EP09786912A
Filing Date
Aug 12, 2009
Status
Revoked
Oct 14, 2024
Grant Date
Oct 25, 2017
External Links
Slate, Register, Google Patents
Similar Patents facing opposition

Bibliography

The patent EP2315587B1 was granted to Actelion Pharmaceuticals on Oct 25, 2017 following the initial filing on Aug 12, 2009 under the application number EP09786912A . The current legal status of the patent is Revoked.

Patent Summary

Patent Family New

Patent Family

Patent Oppositions (5)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

HEXALJul 25, 2018ADMISSIBLE
STADA ARZNEIMITTELJul 24, 2018ADMISSIBLE
TEVA PHARMACEUTICALSJul 24, 2018ADMISSIBLE
ALFRED E TIEFENBACHERJul 23, 2018ADMISSIBLE
GENERICS UKJul 19, 2018ADMISSIBLE

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history, including filings, correspondence, and decisions made by patent offices. These documents are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination. It also includes the oppositions documents filed against the patent.

  • Date

    Description

  • Get instant alerts for new documents